NexgenRx Announces Third Quarter Results (with Continued Significant Increases in EBITDA, Revenue, and Financial Position)
Key Highlights
- ➤Q3 revenue rose 8% to $4,904,857
- ➤Q3 income before taxes increased 48.8% to $843,735
- ➤Q3 EBITDA increased 18.1% to $1,048,210
- ➤Nine-month net income increased 46.7% to $2.2 million
- ➤Cash and cash equivalents totaled $4.1 million at September 30, 2026
Expert Statements
Ron Loucks, President and CEO of NexgenRx Inc.
“The Company delivered a solid performance in the third quarter of 2026, continuing to advance our strategic priorities while maintaining a strong focus on profitable growth and operational execution. Third quarter results demonstrate the strength and scalability of our business model, supported by sustained client demand, growing transaction activity, and our ability to translate business expansion into improved financial performance. Looking ahead, our priorities remain firmly centred on sustainable expansion, operational excellence, and long-term value creation. We will continue to allocate resources toward technology, AI-enabled capabilities, and automation, while pursuing opportunities to deepen client relationships, strengthen our competitive position, and expand our market presence. We remain disciplined in evaluating growth opportunities and committed to balancing investment with financial performance. With a strong financial foundation, an experienced and dedicated team, and a clear strategic direction, we are confident in our ability to build on the progress achieved in 2026 and create enduring value for our shareholders.”
TORONTO, ON / ACCESS Newswire / November 19, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2026, with revenues of $4,904,857, income before taxes of $843,735 and EBITDA of $1,048,210, representing significant percentage increases of 8%, 48.8% and 18.1%, respectively, compared to the same period in 2025.
During the quarter, the Company continued to strengthen the foundations of its business and invested in capabilities that will support its next phase of growth. Technology modernization, digital transformation, and process automation remain key priorities as NexgenRx seeks to enhance service quality, improve productivity, and create greater operating efficiencies. In parallel, the Company's Artificial Intelligence ("AI") Committee continued assessing opportunities and has incorporated several AI-based initiatives into the Company's business operations, with a continued emphasis on practical applications that can improve workflow efficiency, strengthen analytical capabilities, and support more informed decision-making. NexgenRx also remain committed to developing its people and organizational capabilities, recognizing that its team's expertise and execution are fundamental to the Company's long-term success.
Get started
Create a free account to read the full story.
